[go: up one dir, main page]

CL2008001631A1 - Compuestos derivados de heterociclos sustituidos, con la presencia de un grupo fenoxi, inhibidores de transcriptasa inversa; composicion farmaceutica; y uso en el tratamiento de infecciones virales por vih. - Google Patents

Compuestos derivados de heterociclos sustituidos, con la presencia de un grupo fenoxi, inhibidores de transcriptasa inversa; composicion farmaceutica; y uso en el tratamiento de infecciones virales por vih.

Info

Publication number
CL2008001631A1
CL2008001631A1 CL2008001631A CL2008001631A CL2008001631A1 CL 2008001631 A1 CL2008001631 A1 CL 2008001631A1 CL 2008001631 A CL2008001631 A CL 2008001631A CL 2008001631 A CL2008001631 A CL 2008001631A CL 2008001631 A1 CL2008001631 A1 CL 2008001631A1
Authority
CL
Chile
Prior art keywords
treatment
pharmaceutical composition
reverse transcriptase
viral infections
transcriptase inhibitors
Prior art date
Application number
CL2008001631A
Other languages
English (en)
Inventor
Andrew James Sebahar Paul Richard Peat
Michael Youngman
Pek Yoke Chong
Huichang Zhang
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CL2008001631A1 publication Critical patent/CL2008001631A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Furan Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Compuestos derivados de heterociclos de nitrógeno, inhibidores de transcriptasa invesa; composición farmacéutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de infecciones virales como VIH.
CL2008001631A 2007-06-06 2008-06-04 Compuestos derivados de heterociclos sustituidos, con la presencia de un grupo fenoxi, inhibidores de transcriptasa inversa; composicion farmaceutica; y uso en el tratamiento de infecciones virales por vih. CL2008001631A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94226607P 2007-06-06 2007-06-06

Publications (1)

Publication Number Publication Date
CL2008001631A1 true CL2008001631A1 (es) 2009-01-02

Family

ID=40130130

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008001631A CL2008001631A1 (es) 2007-06-06 2008-06-04 Compuestos derivados de heterociclos sustituidos, con la presencia de un grupo fenoxi, inhibidores de transcriptasa inversa; composicion farmaceutica; y uso en el tratamiento de infecciones virales por vih.

Country Status (25)

Country Link
US (1) US8304419B2 (es)
EP (1) EP2166856A4 (es)
JP (1) JP2010529965A (es)
KR (1) KR20100039301A (es)
CN (1) CN101790313A (es)
AR (1) AR066909A1 (es)
AU (1) AU2008261977A1 (es)
BR (1) BRPI0812738A2 (es)
CA (1) CA2694871A1 (es)
CL (1) CL2008001631A1 (es)
CO (1) CO6251246A2 (es)
CR (1) CR11196A (es)
DO (1) DOP2009000266A (es)
EA (1) EA017141B1 (es)
IL (1) IL202217A0 (es)
MA (1) MA31500B1 (es)
MX (1) MX2009013349A (es)
NZ (1) NZ581409A (es)
PE (1) PE20090330A1 (es)
SG (1) SG182162A1 (es)
TW (1) TW200901969A (es)
UA (1) UA98784C2 (es)
UY (1) UY31132A1 (es)
WO (1) WO2008154271A1 (es)
ZA (1) ZA200908604B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2665007A1 (en) * 2006-10-06 2008-05-08 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
WO2010075376A2 (en) * 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
US8546405B2 (en) 2008-12-23 2013-10-01 Abbott Laboratories Anti-viral compounds
JP5734956B2 (ja) 2009-04-15 2015-06-17 アッヴィ・インコーポレイテッド 抗ウィルス化合物
BR112012002333A2 (pt) 2009-08-06 2017-07-18 Neuraltus Pharmaceuticals Inc método de reduzir os efeitos colaterais e método de potencializar o efeito de um imunomodulador administrado a um sujeito que dele necessita; métodos para tratar doença associada com excesso de ativação de monócitos para macrófagos ativados, diabetes tipo ii ou complicações relacionadas, doença associada com a migração de monócitos ou macrófagos ativados, doença associada a excesso de produção de scd14 e/ou scd163 por macrófagos ativados; composto de cloreto de sódio; composição farmacêutica; método para diagnosticar uma doença relacionada com macrófagos em um sujeito; e método para determinar a eficácia do tratamento com um agente oxidante para uma doença relacionada a macrófagos em um sujeito.
JP5851998B2 (ja) * 2009-10-27 2016-02-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 殺虫剤および殺ダニ剤としてのハロアルキル置換アミド
CN110483499A (zh) 2009-11-05 2019-11-22 圣母大学 咪唑并[1,2-a]吡啶类化合物及其合成及使用方法
US8865734B2 (en) 2010-03-18 2014-10-21 Institut Pasteur Korea Anti-infective compounds
EP2571882A1 (en) * 2010-05-21 2013-03-27 Gilead Sciences, Inc. Heterocyclic flaviviridae virus inhibitors
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
EP2511263A1 (en) 2011-04-14 2012-10-17 Phenex Pharmaceuticals AG Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
WO2013149977A1 (en) 2012-04-04 2013-10-10 F. Hoffmann-La Roche Ag 1,2- pyridazine, 1,6- pyridazine or pyrimidine - benzamide derivatives as gpbar1 modulators
JP6278472B2 (ja) 2013-02-27 2018-02-14 塩野義製薬株式会社 Ａｍｐｋ活性化作用を有するインドールおよびアザインドール誘導体
JO3603B1 (ar) * 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
US20180155341A1 (en) 2015-07-02 2018-06-07 Janssen Sciences Ireland Uc Antibacterial Compounds
BR112018005208B1 (pt) 2015-09-17 2023-12-12 Marvin J. Miller Compostos heterocíclicos que contêm benzilamina e composições úteis contra infecção micobacteriana
AU2017286368B2 (en) 2016-06-16 2021-02-25 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacterials
WO2018073828A1 (en) * 2016-10-20 2018-04-26 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Dna primase and gyrase inhibitors
US11224596B2 (en) 2017-03-01 2022-01-18 Janssen Sciences Ireland Unlimited Company PZA and cytochrome bc1 inhibitor combination treatment
CN109748927A (zh) * 2017-11-03 2019-05-14 上海交通大学医学院附属瑞金医院 杂芳基酰胺类化合物、其制备方法、药用组合物及其应用
JP7013048B2 (ja) * 2018-03-02 2022-01-31 国立大学法人大阪大学 タンパク質及び／又はペプチド修飾用分子
WO2019180686A1 (en) * 2018-03-23 2019-09-26 Cmg Pharmaceutical Co., Ltd. Ido-tdo dual inhibitor and related methods of use
CN111954532A (zh) * 2018-04-13 2020-11-17 上海交通大学医学院附属瑞金医院 杂芳基酰胺类化合物的抗肿瘤多药耐药性、治疗癌症的用途和蛋白质-药物分子复合物
CN112996529B (zh) * 2018-10-02 2025-09-02 迪斯克医药公司 Matriptase 2抑制剂及其用途
US10959987B2 (en) 2019-04-15 2021-03-30 King Abdulaziz University Imidazole-based compounds as hepatitis C virus inhibitors
KR102051783B1 (ko) * 2019-09-02 2019-12-03 부산대학교 산학협력단 3,10-이치환 벤조풀벤 유도체의 신규 합성방법
CN119661371A (zh) * 2023-09-13 2025-03-21 帕潘纳(北京)科技有限公司 一种2-氟-4-甲基苯胺的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9716446D0 (en) * 1997-08-05 1997-10-08 Agrevo Uk Ltd Fungicides
JP2000256323A (ja) * 1999-01-08 2000-09-19 Japan Tobacco Inc ２−オキソキノリン化合物及びその医薬用途
DE10161765A1 (de) * 2001-12-15 2003-07-03 Bayer Cropscience Gmbh Substituierte Phenylderivate
JP4736043B2 (ja) 2003-03-14 2011-07-27 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
MXPA06002780A (es) * 2003-09-11 2006-06-14 Tibotec Pharm Ltd Inhibidores de entrada del virus de vih.
WO2005026114A1 (en) 2003-09-17 2005-03-24 Pfizer Inc. Hiv protease inhibitors, compositions containing the same and their pharmaceutical uses
JP2007514659A (ja) * 2003-11-25 2007-06-07 イーライ リリー アンド カンパニー ペルオキシソーム増殖因子活性化受容体の修飾因子
US7166738B2 (en) * 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
MXPA06012252A (es) * 2004-04-23 2006-12-15 Hoffmann La Roche Compuestos no nucleosidos que inhiben la transcriptasa inversa.
US20060004197A1 (en) * 2004-07-02 2006-01-05 Thomas Thrash Sulfonamide-based compounds as protein tyrosine kinase inhibitors
US20060025480A1 (en) 2004-08-02 2006-02-02 Boehringer Ingelheim International Gmbh Benzoic acid derivatives as non nucleoside reverse transcriptase inhibitors
AR057455A1 (es) * 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
US7606430B2 (en) * 2005-08-30 2009-10-20 Asml Netherlands B.V. Lithographic apparatus and device manufacturing method utilizing a multiple dictionary compression method for FPD
CN101679294B (zh) * 2007-05-30 2012-08-08 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂

Also Published As

Publication number Publication date
DOP2009000266A (es) 2010-02-15
SG182162A1 (en) 2012-07-30
PE20090330A1 (es) 2009-04-30
EP2166856A1 (en) 2010-03-31
EP2166856A4 (en) 2012-05-30
CO6251246A2 (es) 2011-02-21
EA017141B1 (ru) 2012-10-30
CA2694871A1 (en) 2008-12-18
US8304419B2 (en) 2012-11-06
UA98784C2 (ru) 2012-06-25
EA200901490A1 (ru) 2010-06-30
US20100216746A1 (en) 2010-08-26
JP2010529965A (ja) 2010-09-02
AU2008261977A1 (en) 2008-12-18
KR20100039301A (ko) 2010-04-15
ZA200908604B (en) 2011-02-23
IL202217A0 (en) 2010-06-16
UY31132A1 (es) 2009-03-31
NZ581409A (en) 2012-03-30
AR066909A1 (es) 2009-09-23
WO2008154271A1 (en) 2008-12-18
BRPI0812738A2 (pt) 2014-09-30
MX2009013349A (es) 2010-01-20
CN101790313A (zh) 2010-07-28
TW200901969A (en) 2009-01-16
CR11196A (es) 2010-03-08
MA31500B1 (fr) 2010-07-01

Similar Documents

Publication Publication Date Title
CL2008001631A1 (es) Compuestos derivados de heterociclos sustituidos, con la presencia de un grupo fenoxi, inhibidores de transcriptasa inversa; composicion farmaceutica; y uso en el tratamiento de infecciones virales por vih.
CL2008000862A1 (es) Compuestos derivados de triazolonas, inhibidores no nucleosidos de transcriptasa inversa; composicion farmaceutica que contiene a dichos compuestos; y uso del compuesto para tratar la infeccion del vih-1.
CL2008003511A1 (es) Compuestos derivados nucleotidicos, inhibidores de polimerasa ns5b del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
CL2015000880A1 (es) Compuestos heterociclicos derivados de 4-pirimidinona, inhibidores de la transcriptasa inversa del vih; composicion farmaceutica; uso en la profilaxis o el tratamiento de infeccion por vih o para la profilaxis, tratamiento o retraso de la aparicion del sida en un sujeto.
CL2008002369A1 (es) Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer.
CL2009000483A1 (es) Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer.
CL2015001864A1 (es) Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih.
CL2016002414A1 (es) Compuestos derivados de nucleosidos, inhibidores de la transcriptasa inversas composición farmacéutica que los comprende y su uso en el tratamiento de una infección por vih. pct
CL2011000191A1 (es) Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
CL2008003405A1 (es) Compuestos derivados de tienopiridina, inhibidores de la enzima integrasa del vih; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una infeccion por vih.
CL2011000454A1 (es) Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
CL2011001333A1 (es) Compuestos derivados de heterociclos nitrogenados sustituidos, inhibidores de ns5a; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
CL2013001141A1 (es) Compuestos derivados de heterociclos condensados, inhibidores del virus de la hepatitis c; composicion farmaceutica que los contiene; y su uso para el tratamiento de la infeccion por el virus de la hepatitis c.
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
CL2016000698A1 (es) Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
CL2016000493A1 (es) Inhibidores de polimerasa hcv.
CL2008001381A1 (es) Compuestos derivados de tripeptidos que contienen heterociclos nitrogenados; composicion farmaceutica que comprende a dichos compuestos; y uso para tratar una infeccion de hepatitis c o vih.
CL2007003594A1 (es) Compuestos derivados de heterociclos condensados de nitrogeno, inhibidores de transcriptasa inversa no nucleosidicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del sida.
CL2010001415A1 (es) Compuestos derivados de diazacarbazol, con actividad inhibidora de quinasa; composición farmacéutica que comprende a uno de los compuestos; y uso de la composición farmacéutica en la preparación de medicamentos para la inhibición del crecimiento celular o el tratamiento de un trastorno hiperproliferativo
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
CL2007003299A1 (es) Compuestos derivados de macrociclos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CL2013001339A1 (es) Compuestos derivados heterociclicos condensados, con actividad antiviral; composicion farmaceutica que los comprende; y su uso para la prevencion o tratamiento de la infeccion de vih.
CR20240363A (es) Compuestos y métodos para el tratamiento de infecciones virales.